Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

NU6102

CDK/cyclin inhibitor
 
ALX-270-419-M001 1 mg 59.00 USD
 
ALX-270-419-M005 5 mg 175.00 USD
Do you need bulk/larger quantities?
 
1,000-fold more potent inhibitor of CDK1/cyclin B (IC50=9.5nM) and CDK2/cyclin A3 (IC50=5.4nM) than NU2058 (Prod. No. ALX-270-394). Selective for CDK1 and CDK2 compared to CDK4/D1 (IC50=1.6µM), DYRK1A (IC50=0.9µM), PDK1 (IC50=0.8µM) and ROCKII (IC50=0.6µM).

Product Specification

Formula:C18H22N6O3S
 
MW:402.5
 
CAS:444722-95-6
 
Purity:≥95% (HPLC)
 
Appearance:White to off-white solid.
 
Solubility:Soluble in DMSO.
 
Shipping:Ambient
 
Long Term Storage:-20°C
 
Handling:Protect from light. Packaged under inert gas.
 
270-419
Please mouse over
270-419

Product Literature References

N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2: I.R. Hardcastle, et al.; J. Med. Chem. 47, 3710 (2004), Abstract;
Structure-based design of 2-arylamino-4-cyclohexylmethyl-5-nitroso-6-aminopyrimidine inhibitors of cyclin-dependent kinases 1 and 2: K.L. Sayle, et al.; Bioorg. Med. Chem. Lett. 13, 3079 (2003), Abstract;
Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor: T.G. Davies, et al.; Nat. Struct. Biol. 9, 745 (2002), Abstract;

Related Products

NU2058 

CDK inhibitor
161058-83-9 | Print as PDF
 
ALX-270-394-M005 5 mg 87.00 USD
 
ALX-270-394-M025 25 mg 349.00 USD
Do you need bulk/larger quantities?
 

Product Toolbox

PRODUCT RESOURCES

Print as PDF
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
CDK
Cyclin
By biological activity:
CDK Inhibitor
Cyclin Inhibitor
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Related Literature

Product Flyers
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Cell Cycle - Mitosis, CDKS & Cell Cycle Signaling
Download as PDF

All new literature pieces

Recommend this page

 
Keep in touch

©2017 Enzo Life Sciences, Inc.,